U.S. markets close in 49 minutes
  • S&P 500

    4,394.32
    -27.98 (-0.63%)
     
  • Dow 30

    35,001.89
    -142.42 (-0.41%)
     
  • Nasdaq

    14,646.89
    -193.83 (-1.31%)
     
  • Russell 2000

    2,187.06
    -29.86 (-1.35%)
     
  • Crude Oil

    71.60
    -0.31 (-0.43%)
     
  • Gold

    1,799.70
    +0.50 (+0.03%)
     
  • Silver

    24.75
    -0.57 (-2.24%)
     
  • EUR/USD

    1.1825
    +0.0017 (+0.14%)
     
  • 10-Yr Bond

    1.2380
    -0.0380 (-2.98%)
     
  • GBP/USD

    1.3885
    +0.0061 (+0.44%)
     
  • USD/JPY

    109.7490
    -0.6260 (-0.57%)
     
  • BTC-USD

    37,974.25
    -1,912.03 (-4.79%)
     
  • CMC Crypto 200

    898.80
    +22.57 (+2.58%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Titan Medical Stock Jumps After Medtronic's $10M Second Milestone Payment

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Titan Medical Inc (NASDAQ: TMDI) has received million under the second technical milestone under the development and license agreement with Medtronic plc (NYSE: MDT).

  • The development and license agreement provides for developing robotic-assisted surgical technologies for Titan and Medtronic in their respective businesses. Titan retains worldwide rights to commercialize the developed technologies for use with its own Enos robotic single access surgical system.

  • In October 2020, Titan achieved the first technical milestone and completed a non-technical financial milestone under the development agreement, with the satisfactory raising of $18 million capital.

  • Titan would receive an additional payment of approximately $11 million on completing the third technical milestone, representing the fourth and final milestone.

  • Price Action: TMDI shares are up 9.84% at $2.01, and MDT shares are up 0.68% at $126 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.